

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

SIGLEC6 RABBIT PAB

货号: S212818

产品全名: SIGLEC6 兔多抗

基因符号 CD327; CD33L; OBBP1; CD33L1; CD33L2; CDW327 UNIPROT ID: O43699 (Gene Accession - BC035359)

背景: This gene encodes a member of the SIGLEC (sialic acid binding immunoglobulin-like lectin) family of proteins. The encoded transmembrane receptor binds sialyl-TN glycans and leptin. Placental expression of the encoded protein is upregulated in preeclampsia.

抗原: Fusion protein of human SIGLEC6

经过测试的应用: ELISA, WB, IHC

推荐稀释比: IHC: 40-200;WB: 500-2000;ELISA: 5000-10000

种属反应性: Rabbit 克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification

种属反应性: Human

成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol


研究领域: Immunology

储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Product Description

Pioneering GTPase and Oncogene Product Development since 2010




Immunohistochemistry analysis of paraffin embedded Human breast cancer tissue using 212818(SIGLEC6 Antibody) at a dilution of 1/50(Cytoplasm).


In comparision with the IHC on the left, the same paraffin-embedded Human breast cancer tissue is first treated with the fusion protein and then with 212818(Anti-SIGLEC6 Antibody) at dilution 1/50.



The image on the left is immunohistochemistry of paraffinembedded Human liver cancer tissue using 212818(Anti-SIGLEC6 Antibody) at a dilution of 1/50.



In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with fusion protein and then with D125880(Anti-SIGLEC6 Antibody) at dilution 1/50.



Gel: 8%SDS-PAGE, Lysate: 40 µg; Lane 1-2: Human right lower lung tissue and Human plasma solution

Primary antibody: 212818(SIGLEC6 Antibody) at dilution 1/650;

Secondary antibody: HRP-conjugated Goat anti rabbit IgG at 1/5000 dilution;

Exposure time: 30 seconds



Product Description

Pioneering GTPase and Oncogene Product Development since 2010